Regulatory & Compliance

Lifestyle Changes Triumph Over Metformin in Diabetes Prevention
Research & Development Lifestyle Changes Triumph Over Metformin in Diabetes Prevention

The prevalence of diabetes presents an escalating health crisis with significant implications for individuals and healthcare systems globally. Among prediabetes patients, effective prevention strategies are vital to curb the increasing rates of Type 2 diabetes. Long-term studies underscore that

Are Patient-Friendly Drug Formulations the Future of Cancer Care?
Management & Regulatory Are Patient-Friendly Drug Formulations the Future of Cancer Care?

The field of cancer treatment has witnessed significant innovations, especially in the formulation of drugs designed to ease patient administration. The European Medicines Agency's endorsement of zanubrutinib tablets, Brukinsa's newer form, highlights an essential shift toward treatments that

FDA Approves Gamifant for Treating Macrophage Activation Syndrome
Management & Regulatory FDA Approves Gamifant for Treating Macrophage Activation Syndrome

In the world of biopharmaceutical innovations, Ivan Kairatov stands out as an expert in tech and development. His insights into the recent FDA approval of Gamifant are invaluable, particularly regarding its role in treating macrophage activation syndrome (MAS) associated with Still's disease. This

Is Sarclisa a Game Changer for Multiple Myeloma Treatment?
Research & Development Is Sarclisa a Game Changer for Multiple Myeloma Treatment?

In recent times, Sanofi's Sarclisa (isatuximab) has emerged as a promising advancement in the treatment of multiple myeloma (MM), a type of blood cancer. Approximately 46,000 new cases are diagnosed annually in Europe alone, making MM the second most prevalent blood cancer after non-Hodgkin

EMA Recommends Cabometyx for Advanced Neuroendocrine Tumors
Management & Regulatory EMA Recommends Cabometyx for Advanced Neuroendocrine Tumors

In the realm of medical advancements, addressing the challenge of treating advanced neuroendocrine tumors (NETs) is crucial, given their complex nature and slow progression. These tumors arise from neuroendocrine cells dispersed throughout the body, posing significant treatment demands. A pivotal

Hetronifly Approved by UK to Treat Aggressive Lung Cancer
Management & Regulatory Hetronifly Approved by UK to Treat Aggressive Lung Cancer

The UK has taken a monumental step in the fight against extensive-stage small cell lung cancer (SCLC) with the recent approval of Hetronifly. This approval by the Medicines and Healthcare products Regulatory Agency (MHRA) introduces Hetronifly as the first anti-PD-1 monoclonal antibody available in

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later